Does the Ingestion of Mycoprotein Elicit an Optimal Anabolic Response in Resting and Exercised Skeletal Muscle?
ARM
1 other identifier
interventional
20
1 country
1
Brief Summary
The present study will seek to quantify the muscle protein synthetic response to mycoprotein feeding, comparing it to milk protein as a gold standard and heavily researched positive control
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable healthy
Started Jan 2017
Longer than P75 for not_applicable healthy
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 2, 2016
CompletedFirst Posted
Study publicly available on registry
December 6, 2016
CompletedStudy Start
First participant enrolled
January 26, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2022
CompletedApril 30, 2025
April 1, 2025
1.3 years
December 2, 2016
April 25, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Muscle fractional synthetic rate (muscle protein synthesis)
7.5 hours
Secondary Outcomes (3)
Plasma amino acid concentration
7.5 hours
Serum insulin concentration
7.5 hours
Molecular markers of muscle anabolism
7.5 hours
Study Arms (2)
Mycoprotein beverage
ACTIVE COMPARATORMilk protein beverage
PLACEBO COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- BMI between 18 and 30 -
You may not qualify if:
- Any diagnosed metabolic impairment (e.g. type 1 or 2 Diabetes)
- Any diagnosed cardiovascular disease or hypertension.
- Elevated blood pressure at the time of screening (e.g. blood pressure of ≥140/90mmHg).
- Chronic use of any prescribed or over the counter pharmaceuticals.
- A personal or family history of epilepsy, seizures or schizophrenia.
- Anyone with previous motor disorders.
- An allergy to mycoprotein / Quorn, penicillin, or milk.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Exeter, Sports & Health Sciences, College of Life & Environmental Sciences
Exeter, Devon, EX1 2LU, United Kingdom
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 2, 2016
First Posted
December 6, 2016
Study Start
January 26, 2017
Primary Completion
May 1, 2018
Study Completion
May 1, 2022
Last Updated
April 30, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share